Bevacizumab increases risk of high-grade CHF

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2014年 / 1520卷 / 1期
关键词：
D O I：
10.1007/s40278-014-3594-3
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：7 / 7
相关论文
共 50 条
  • [31] Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study
    Vidal, Adriana C.
    Howard, Lauren E.
    Moreira, Daniel M.
    Castro-Santamaria, Ramiro
    Andriole, Gerald L., Jr.
    Freedland, Stephen J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (12) : 2936 - 2942
  • [32] OBESITY INCREASES THE RISK FOR HIGH-GRADE PROSTATE CANCER: RESULTS FROM THE REDUCE STUDY
    Freedland, Stephen
    Gerber, Leah
    Banez, Lionel L.
    Moreira, Daniel M.
    Andriole, Gerald L.
    Rittmaster, Roger S.
    JOURNAL OF UROLOGY, 2011, 185 (04): : E66 - E66
  • [33] Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients
    Schernberg, A.
    Dhermain, F.
    Ammari, S.
    Dumont, S. N.
    Domont, J.
    Patrikidou, A.
    Pallud, J.
    Dezamis, E.
    Deutsch, E.
    Louvel, G.
    CANCER RADIOTHERAPIE, 2018, 22 (01): : 9 - 16
  • [34] OUTCOMES IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (HGG) TREATED WITH BEVACIZUMAB
    Ye, L.
    Hasani, A.
    Nowak, A.
    King, A.
    Long, A.
    Trevenen, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 72 - 72
  • [35] Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma
    Smith, Katrina H.
    Lee, Eudocia Quant
    Muzikansky, Alona
    Robins, Elizabeth
    Duda, Gerstner Dan G.
    Reardon, David A.
    Nayak, Lakshmi
    Norden, Andrew David
    Doherty, Lisa M.
    Rifenburg, Jennifer
    LaFrankie, Debra C.
    Ruland, Sandra
    Pulverenti, Julee
    Stokes, Deirdre
    Lam, Priscilla
    McCluskey, Christine Sceppa
    Gaffey, Sarah C.
    Batchelor, Tracy
    Jain, Ftakesh K.
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] IRRADIATION AND BEVACIZUMAB IN HIGH-GRADE GLIOMA RE-TREATMENT SETTINGS
    Niyazi, M.
    Ganswindt, U.
    Schwarz, S. B.
    Tonn, J. C.
    Geisler, J.
    Siefert, A.
    Belka, C.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S263 - S263
  • [37] Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
    Bai, Xuexue
    Xing, Hao
    Feng, Ming
    Ma, Wenbin
    Wang, Shiyong
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1617 - 1626
  • [38] Platelet count and bevacizumab response in high-grade glioma patients.
    de Oliveira Ferreira, Patricia Alves
    Oliveira Fernandes, Viviane Teodoro
    Santos, Fabio Nasser
    Balleiro Anastacio da Costa, Alexandre Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Single-agent bevacizumab for recurrent high-grade glioma.
    Greally, Megan
    Cadoo, Karen Anne
    Coleman, Niamh
    O'Brien, Michelle
    O'Riordan, Lynda M.
    Grogan, William
    Breathnach, Oscar S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] PHASE I STUDYOF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA
    Lee, Eudocia
    Smith, Katrina
    Muzikansky, Alona
    Gerstner, Elizabeth
    Kuhn, John
    Reardon, David
    Nayak, Lakshmi
    Norden, Andrew
    Rifenburg, Jennifer
    Pulverenti, Julee
    Stokes, Deirdre
    Lam, Priscilla
    Martins, Tiago
    Hempfling, Kelly
    McCluskey, Christine
    Gaffey, Sarah
    Batchelor, Tracy
    Duda, Dan
    Jain, Rakesh
    Wen, Patrick
    NEURO-ONCOLOGY, 2014, 16
12345